IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.101
AS - Asia 4.503
EU - Europa 2.961
SA - Sud America 622
AF - Africa 264
Continente sconosciuto - Info sul continente non disponibili 167
OC - Oceania 11
Totale 13.629
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.924
SG - Singapore 1.548
IT - Italia 1.116
CN - Cina 878
VN - Vietnam 803
BR - Brasile 470
HK - Hong Kong 363
BD - Bangladesh 352
IE - Irlanda 329
SE - Svezia 283
DE - Germania 281
FR - Francia 214
ZA - Sudafrica 169
NL - Olanda 144
IN - India 140
GB - Regno Unito 120
RU - Federazione Russa 99
CA - Canada 92
AT - Austria 84
FI - Finlandia 76
AR - Argentina 59
TR - Turchia 48
MX - Messico 46
KR - Corea 45
IQ - Iraq 42
JP - Giappone 38
ES - Italia 35
PH - Filippine 35
ID - Indonesia 34
CZ - Repubblica Ceca 29
PK - Pakistan 29
PL - Polonia 29
BE - Belgio 28
CI - Costa d'Avorio 28
EC - Ecuador 27
UZ - Uzbekistan 23
CO - Colombia 22
UA - Ucraina 22
TH - Thailandia 21
MA - Marocco 17
VE - Venezuela 16
IR - Iran 13
LT - Lituania 13
TW - Taiwan 13
EG - Egitto 11
TN - Tunisia 11
AU - Australia 10
CL - Cile 10
JO - Giordania 10
LU - Lussemburgo 10
MY - Malesia 10
SA - Arabia Saudita 10
KE - Kenya 9
HN - Honduras 8
BG - Bulgaria 7
PY - Paraguay 7
AZ - Azerbaigian 6
CR - Costa Rica 6
IL - Israele 6
KZ - Kazakistan 6
JM - Giamaica 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
EE - Estonia 4
KH - Cambogia 4
NG - Nigeria 4
OM - Oman 4
BB - Barbados 3
BO - Bolivia 3
DK - Danimarca 3
GR - Grecia 3
GT - Guatemala 3
HU - Ungheria 3
MD - Moldavia 3
MK - Macedonia 3
NI - Nicaragua 3
PA - Panama 3
PE - Perù 3
PS - Palestinian Territory 3
RS - Serbia 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GY - Guiana 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 13.445
Salva come PNG Salva come JPEG
Città #
Singapore 898
Ashburn 735
San Jose 582
Dallas 510
Santa Clara 372
Hong Kong 341
Dublin 325
Chandler 313
Ho Chi Minh City 246
Council Bluffs 208
Boardman 199
Parma 198
Beijing 195
Hanoi 174
Johannesburg 157
Los Angeles 148
New York 146
Munich 131
Ann Arbor 126
Shanghai 104
Lauterbourg 95
Hefei 94
Bologna 93
Milan 93
Vienna 64
Rome 53
Buffalo 52
São Paulo 47
Chicago 42
Bremen 41
Da Nang 40
Helsinki 40
Moscow 38
Princeton 38
Columbus 36
Frankfurt am Main 36
Montreal 34
Dearborn 33
Marseille 33
Modena 32
Seoul 32
Nuremberg 30
Atlanta 29
Abidjan 28
Haiphong 28
Nanjing 27
Tokyo 27
Brussels 26
London 26
Turku 26
Toronto 25
Verona 25
Orem 23
Chennai 22
Denver 22
West Jordan 22
The Dalles 21
Seattle 20
Warsaw 20
Amsterdam 19
Bengaluru 19
Boston 19
Houston 19
Brooklyn 18
Des Moines 18
Phoenix 18
Reggio Emilia 18
Guangzhou 17
Mexico City 17
Tashkent 17
Baghdad 16
Brno 15
Jakarta 15
Pune 15
Rio Saliceto 15
Wilmington 15
Jinan 14
Poplar 14
Lahore 13
Naples 13
Redondo Beach 13
Rio de Janeiro 13
Tianjin 13
Venice 13
Belo Horizonte 12
Biên Hòa 12
Florence 12
Stockholm 12
Fremont 11
Hải Dương 11
Izmir 11
Amman 10
Brescia 10
Düsseldorf 10
Guayaquil 10
Torrile 10
Trento 10
Brasília 9
Buenos Aires 9
Chongqing 9
Totale 8.185
Salva come PNG Salva come JPEG
Nome #
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 249
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 222
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 216
227P Sexual dimorphism in immune profile of early and advanced NSCLC 207
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 207
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 206
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 205
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 199
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 198
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 197
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 197
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 191
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 190
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 188
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 187
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 181
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 181
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 180
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 179
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 178
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 176
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 172
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 169
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 169
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 166
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 162
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 162
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 160
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 158
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 157
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 157
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 156
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 156
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 156
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 155
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 152
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 146
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 146
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 144
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 141
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 139
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 138
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 137
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 134
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 131
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 129
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 128
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 127
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 126
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 125
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 124
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 124
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 124
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 123
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 123
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 123
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 121
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 121
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 120
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 119
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 117
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 117
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 117
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 115
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 115
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 115
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 115
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 114
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 113
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 112
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 112
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 110
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 110
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 103
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 103
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 102
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 99
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 98
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 98
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 98
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 96
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 96
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 95
The radiological appearances of lung cancer treated with immunotherapy: a review 92
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 88
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 87
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 83
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 78
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 76
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 75
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 75
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 74
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 74
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 73
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 73
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 71
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 69
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 68
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 65
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 62
Totale 13.407
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.657
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.657
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022246 0 0 15 19 5 12 60 10 6 10 21 88
2022/20231.306 121 129 72 109 143 143 38 73 391 7 56 24
2023/2024876 33 60 28 36 110 157 97 36 62 80 49 128
2024/20252.804 92 177 226 197 261 244 183 132 253 271 237 531
2025/20267.113 582 512 983 604 796 374 630 322 930 557 456 367
2026/2027630 259 371 0 0 0 0 0 0 0 0 0 0
Totale 13.629